Clinical trials: Malaria
Malaria
Comparison of Three Plasmodium Falciparum Isolates in a Controlled Human Malaria Infection
An effective vaccine against malaria is urgently needed to combat the scourge of this disease. Before candidate vaccines can be tested in endemic countries, they are first tested in human volunteers in so-called Controlled Human…
- Trial name
- TIP3 (NCT01627951)
- Testing
- NF54, NF135, NF166
- Where
- 2 sites in Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Malaria
Cohort Event Monitoring in Sub Saharan Africa
This cohort event monitoring will document real-life safety experiences following the intake of Injectable AS. Specifically, the study will record common adverse events that are associated with the use of Inj.
- Trial name
- CEMISA (NCT02817919)
- Where
- 4 sites in Ghana
- Volunteers
- 1,126 people
- Sponsor
- African Collaborating Centre for Pharmacovigilance
Malaria
Consistency of Immunogenicity and Non Inferiority of GSK Biologicals' Candidate Malaria Vaccine Lots in Children
The purpose of this study is to show the consistency of different lots of a candidate vaccine (257049) against malaria developed by GlaxoSmithKline (GSK) Biologicals.
- Trial name
- NCT01323972
- Testing
- GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049)
- Where
- 2 sites in Nigeria
- Volunteers
- 327 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Plasmodium Falciparum Malaria
Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M Adjuvant
Assessing the safety, immunogenicity and ex-vivo efficacy of two transmission blocking vaccines (Pfs25-IMX313 in Matrix M and Pfs48/45 in Matrix M alone and co-administered) in Burkina Faso, in 18-45 years, 12-17 years and 05-11…
- Trial name
- NCT06549257
- Testing
- Pfs25-IMX313, Pfs48/45
- Where
- Burkina Faso
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Plasmodium Falciparum Malaria
Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria
The primary trial objective is to determine the clinically effective dose of orally administered pyronaridine/artesunate (Pyramax®, PA) with a 3:1 ratio to treat adults with acute, symptomatic, uncomplicated P.
- Trial name
- NCT01594931
- Testing
- pyronaridine/artesunate
- Where
- 6 sites in Cambodia, Indonesia and 4 more
- Volunteers
- 477 people
- Sponsor
- Medicines for Malaria Venture
Severe Malaria, Severe Anemia
PDMC Implementation Trial in Kenya
The goal of this implementation trial is to evaluate at least two alternative delivery strategies and adherence support for malaria chemoprevention with dihydroartemisinin-piperaquine in the post-discharge management of children…
- Trial name
- PDMC-SL (NCT06624631)
- Testing
- SMS reminders; adherence support strategy a, Community Health Promoters (CHP) home visits; adherence support strategy b, No reminders; adherence support strategy c
- Where
- Kenya
- Volunteers
- 600 people
- Sponsor
- Liverpool School of Tropical Medicine
Malaria
Broad One Health Endectocide-based Malaria Intervention in Africa (BOHEMIA)
The BOHEMIA program consists of a combination of studies organized around a central community prevention mass drug administration protocol and four sub-studies (i.e.; social science, entomology, health economics, and…
- Trial name
- BOHEMIA (NCT04966702)
- Testing
- Albendazole Pill, Ivermectin Pill, Ivermectin Injectable Product
- Where
- 2 sites in Kenya, Mozambique
- Volunteers
- 48,145 people, healthy volunteers welcome
- Sponsor
- Barcelona Institute for Global Health
Malaria
ATAQ EASY: Artesunate + Amodiaquine Fixed Dose Combination in the Treatment of Uncomplicated Plasmodium Falciparum Malaria
Primary Objective: To demonstrate the non-inferiority, in terms of clinical and parasitological efficacy on D28 of administration of Coarsucam™ (artesunate+amodiaquine fixed-dose combination), as a single daily dose, in…
- Trial name
- NCT00316329
- Testing
- Artesunate + Amodiaquine
- Where
- 5 sites in Cameroon, Madagascar and 2 more
- Volunteers
- 1,032 people
- Sponsor
- Sanofi
Malaria
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
This is a pilot, double-blind, randomized, parallel-group, placebo-control, exploratory study to evaluate the efficacy and safety of 5-aminolevulinic acid hydrochloride (5-ALA HCl) and sodium ferrous citrate (SFC) added on…
- Trial name
- NCT04020653
- Testing
- 5-aminolevulinic acid hydrochloride (5-ALA HCl) 600 mg QD, Sodium ferrous citrate (SFC) 472 mg QD, Artemisinin-based combination (ACT)
- Sponsor
- Neopharma Japan Co., Ltd.
Malaria, Falciparum Malaria
Malaria Molecular Surveillance in Mozambique (Phase 2)
Mozambique is among the ten countries with the highest burden of malaria worldwide, with an estimated 10.3 million cases in 2021.
- Conditions
- Malaria, Falciparum Malaria, Malaria in Pregnancy
- Trial name
- GenMoz2 (NCT06529237)
- Testing
- LDH-based malaria rapid diagnostic test, Malaria rapid diagnostic test
- Where
- Mozambique
- Volunteers
- 18,750 people, healthy volunteers welcome
- Sponsor
- Centro de Investigacao em Saude de Manhica
Plasmodium Falciparum
Comparison of Arterolane-piperaquine Versus Arterolane-piperaquine+Mefloquine Versus Artemether-lumefantrine in Kenyan Children
This open-label randomised controlled clinical trial will compare the safety, tolerability, therapeutic efficacy and pharmacokinetics and pharmacodynamics of arterolane-piperaquine, arterolane-piperaquine plus mefloquine versus…
- Trial name
- TACTKenya (NCT03452475)
- Testing
- Arterolane-piperaquine, Arterolane-piperaquine+mefloquine, Artemether-lumefantrine
- Where
- Kenya
- Volunteers
- 219 people
- Sponsor
- University of Oxford
Malaria
Safety of Primaquine + Artemether-lumefantrine in G6PD Deficient Males With an Asymptomatic Malaria Infection (SAFEPRIM)
The purpose of this study is to evaluate the tolerability and safety of increasing doses of primaquine in combination with artemether-lumefantrine in G6PD deficient males with an asymptomatic P. falciparum malaria infection.
- Trial name
- NCT02174900
- Testing
- Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine, Artemether-Lumefantrine (AL) combination, Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine
- Where
- Burkina Faso
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Plasmodium Falciparum Infection, Malaria
L9LS MAb in Malian Adults
The purpose of this study is to evaluate the safety and tolerability of a one time SC administration of L9LS in healthy adults in Mali, as well as its protective efficacy against naturally occurring Plasmodium falciparum (Pf)…
- Trial name
- NCT05816330
- Testing
- L9LS (VRC-MALMAB0114-00-AB)
- Where
- 3 sites in Mali
- Volunteers
- 490 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Ethiopia Malaria Therapeutic Efficacy Study
In this stdy, patients aged above 6 months with symptomatic malaria presenting to health centers will be enrolled for treatment with artemether-lumefantrine for P.
- Trial name
- NCT01052584
- Testing
- Chloroquine- P. vivax, Artemether-Lumefantrine: P. vivax, Artemether-lumefantrine: P. falciparum
- Where
- 2 sites in Ethiopia
- Volunteers
- 354 people
- Sponsor
- Centers for Disease Control and Prevention
Malaria, Falciparum
Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria
Chlorproguanil-dapsone has been approved for the treatment of uncomplicated Plasmodium falciparum malaria in a number of countries across sub-Sahara Africa, and by the UK's Medicines and Healthcare products Regulatory Agency.
- Trial name
- NCT00344006
- Testing
- chlorproguanil-dapsone-artesunate, artemether-lumefantrine
- Where
- 9 sites in Burkina Faso, Ghana and 3 more
- Volunteers
- 1,395 people
- Sponsor
- GlaxoSmithKline
Malaria, Bacteremia
Empirical ANtibiotic THErapy in Adults Hospitalised With Malaria
While World Health Organization (WHO) guidelines recommend empirical antibacterial therapy as the standard of care in all African children with severe falciparum malaria, there are fewer data to guide the management of adults…
- Conditions
- Malaria, Bacteremia, Sepsis
- Trial name
- ANTHEM (NCT03224052)
- Where
- Burma
- Volunteers
- 20 people
- Sponsor
- Menzies School of Health Research
Severe Malaria
Inhaled Nitric Oxide for the Adjunctive Therapy of Severe Malaria: a Randomized Controlled Trial
Despite the use of highly effective anti-malarial medications, 10-30% of African children with severe malaria will die, underscoring the need for adjunctive therapies that can be applied in endemic areas.
- Trial name
- NCT01255215
- Testing
- Inhaled Nitric Oxide
- Where
- Uganda
- Volunteers
- 180 people
- Sponsor
- University Health Network, Toronto
Malaria, HIV Infections
Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women
This study is an open-label, single site, randomized controlled trial comparing protease inhibitor (PI)-based antiretroviral therapy (ART) to non-PI based ART for HIV-infected pregnant and breastfeeding women of all CD4 cell…
- Trial name
- PROMOTE-PIs (NCT00993031)
- Testing
- Lopinavir/ritonavir, Efavirenz, Zidovudine
- Where
- Uganda
- Volunteers
- 389 people
- Sponsor
- University of California, San Francisco
Malaria
Effectiveness of OZ439 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Volunteers
A single centre, open, controlled study using Blood Stage Plasmodium falciparum challenge inoculum (BSPC) as a model to assess the effectiveness of three dose levels of the experimental anti-malarial product, OZ439.
- Trial name
- NCT02453581
- Testing
- OZ439
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
Comparison of Three Drug Combinations for Intermittent Treatment of Malaria in Children
Intermittent preventive treatment (IPT) offers a way of preventing malaria infection without compromising the development of malaria immunity or encouraging drug resistance.
- Trial name
- NCT00561899
- Testing
- SP, amodiaquine, piperaquine, dihdroartemisinin, intermittent preventive treatment, Du-Cotecxin
- Where
- The Gambia
- Volunteers
- 1,295 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine